Nursing Perspectives on the Increasing Role of PARP Inhibitors for Ovarian Cancer
This webcast is not certified for contact hours.
Release Date: November 18, 2020
Expiration Date: November 18, 2021
Given the approval of multiple novel PARP inhibitors, as well as the associated volume of emerging data and indications, it is critical that nurses be able to evaluate the benefits of these agents, especially efficacy and safety data from recent clinical trials. Thus, expert guidance is needed to help nurses use existing PARP inhibitors safely and effectively, manage adverse events as they occur, as well as plan for optimal integration of new indications into practice when they become available.
The target audience for this activity is oncology nurses, nurse practitioners, and other clinicians who treat patients with ovarian cancer.
After completing this activity, participants should be able to:
- Discuss patient and disease related factors that help identify patients appropriate for PARP inhibitor maintenance therapy
- Review clinical trial data of approved and emerging PARP inhibitor therapy strategies
- Evaluate nursing interventions and management strategies that help prevent PARP-related adverse events and encourage patient adherence to oral therapies
- Examine patient perspective of PARP inhibitor therapy and nursing approaches that enhanced their experience during treatment
Patient Selection for PARP Inhibitor Therapy: What Patient and Disease Factors Impact Treatment Selection?
Paula J. Anastasia, RN, MN, AOCN
Frontline and Secondline PARP Maintenance Strategies: Interpresting the Clinical Trial Data
Shannon Westin, MD, MPH
Non-Maintenance Strategies: How to Use PARP Inhibitors in Recurrent Disease
Chrisann Winslow, RN, BSN, MSN(R), AOCN
Nursing Strategies for Patients Receiving PARP Inhibitors: Improving Safety and Encouraging Oral Adherence
Chrisann Winslow, RN, BSN, MSN(R), AOCN
A Patient's Perspective of PARP Inhibitor Therapy and Relationship with Care Team
Method of Participation
There are no fees for viewing this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) (provider) and Bio Ascend.
All planners and faculty participating in continuing education activities provided by the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
The following speakers and planning committee members listed below have stated they have no financial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity.
• Paula Anastasia, RN, MN, AOCN
• Kelly Chase, MA
• Dru S. Dace, PhD
• Heidi Keeler, PhD, RN
• Renee Paulin, MSN, RN, CWOCN
• Chrisann Winslow, RN, BSN, MSN(R), AOCN
• Cathy – Patient Presenter
The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information they planned and/or present is done so fairly and without bias:
Shannon Westin, MD, MPH is a consultant for AstraZeneca, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Novartis, Eisai, Pfizer, Merck, and Zentalis. Dr. Westin states that she has received research support paid to the institution for which she works from AstraZeneca, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Novartis, ArQule, Bayer, and Cotinga Pharmaceuticals.
Non-Endorsement of Products
Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.
This activity is supported by an educational grant from GlaxoSmithKline.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.